Abstract:Abstract Background Chimeric antigen receptor (CAR) T-cell therapy is a rapidly evolving immunotherapy for hematological malignancies. With increasing access to this modality, there is an urgent need for a comprehensive understanding of infectious complications to optimize prophylaxis and improve clinical outcomes. We conducted a meta-analysis to assess the incidence and types of infectious complications in adult patients receiving CAR T-cell therapy. Methods The study was registered on PROSPERO and we searched 5 electronic databases from inception to 2022. Each author independently screened titles, reviewed full texts to identify eligible studies and extracted data from included studies using Covidence, a data extraction tool for conduction of standard systematic reviews. A random effects model was used, and proportions were used as a measure of outcome. We assessed heterogeneity using I^2 statistic. Risk of bias assessments were conducted using the RoB 2.0 for RCTs and ROBINS I tool for non-RCTs. Results Our search identified 12,441 studies of which 363 underwent full-text review. 33 studies were eligible for inclusion in the analysis and enrolled a total of 2866 patients. The pooled incidence of an infectious event in adult patients after CAR T-cell therapy was 38% (95%CI 0.31, 0.46; p< 0.01; I2 = 98%]. No significant difference was noted in the incidence among studies with a longer follow up duration compared to studies with follow up of ≤ 30 days [40% (95% CI 0.30-0.50) vs 32% (95% CI 0.24-0.40), p=0.20 respectively]. BCMA-directed CAR T-cell therapies used for management of multiple myeloma had a significantly higher incidence of infectious complications compared to CD19 targeted agents, 64% (95% CI 0.53-0.74, I2 = 65%) versus 39% (95% CI 0.30-0.49; I2 = 98%; p < 0.01) respectively, Figure 1. Clostridium difficile and Escherichia coli were the most common pathogens causing bacterial infections, while cytomegalovirus was the most commonly identified viral pathogen. Figure 1. Subgroup analysis of the pooled incidence of infectious events after CAR T-cell therapy among adult patients with hematologic malignancies Conclusion In this study, BCMA-directed CAR T-cell therapies were associated with a significantly higher risk of infectious complications. The results of this study can guide the development of strategies to prevent and manage infectious complications in this patient population. Disclosures Jon Arnason, MD, BMS: Advisor/Consultant|Regeneron: Advisor/Consultant Carolyn D. Alonso, MD, Academy for Continued Healthcare Learning: Honoraria|AiCuris: Advisor/Consultant|American Society of Healthcare Pharmacists: Honoraria|Cidara Therapeutics: Advisor/Consultant|Clinical Care Options: Honoraria|Merck: Advisor/Consultant|Merck: Grant/Research Support

Chimeric antigen receptor-T-cell therapies going viral: latent and incidental viral infections

Improving the safety of CAR‐T‐cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B‐cell lymphoma undergoing CAR‐T‐cell therapy

Infections following chimeric antigen receptor T cell therapy: 2018-2022

2694. Infectious Complications in CAR-T Cell Therapy Recipients: A Systematic Review and Meta-Analysis

Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma

Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy

Infections in Hematologic Malignancy Patients Treated by CD19 Chimeric Antigen Receptor T‐cell Therapy

Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy

Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature

Infectious Complications Following CD30 Chimeric Antigen Receptor T-Cell Therapy in Adults

Infections associated with CAR‐T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies

Cytomegaloviral infections in recipients of chimeric antigen receptor T cell therapy: an observational study with focus on oncologic outcomes

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections

Overview of infectious complications among CAR T- cell therapy recipients

Non-viral vectors for chimeric antigen receptor immunotherapy

Expanding the horizon of transient CAR T therapeutics using virus-free technology

Infectious complications of car T‐cell therapy: A longitudinal risk model

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19